Request Demo
Last update 23 Jan 2025
Tizetatug rezetecan
Last update 23 Jan 2025
Overview
Basic Info
Drug Type Antibody drug conjugate (ADC) |
Synonyms SHR A1921, SHR-1921, SHR-A1921 + [1] |
Target |
Mechanism Trop-2 inhibitors(Tumor-associated calcium signal transducer 2 inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationFast Track (US), Breakthrough Therapy (CN) |
Login to view timeline
Structure/Sequence
Sequence Code 27958L
Source: *****
Sequence Code 774044794H
Source: *****
Related
24
Clinical Trials associated with Tizetatug rezetecanNCT06470672
A Phase 2 Study of SHR-A1921 Combined Adebrelimab in Endocrine Therapy-failed HR-positive, HER2-negative Advanced Breast Cancer
NCT06649331
Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer：A Prospective, Open-label, Multicenter, Phase II Trial
CTR20242710
HRS-4642联合抗肿瘤药物在晚期实体瘤受试者中的安全性、耐受性及有效性的IB /II期临床研究
[Translation] Phase IB/II clinical study on the safety, tolerability and efficacy of HRS-4642 combined with anti-tumor drugs in subjects with advanced solid tumors
100 Clinical Results associated with Tizetatug rezetecan
Login to view more data
100 Translational Medicine associated with Tizetatug rezetecan
Login to view more data
100 Patents (Medical) associated with Tizetatug rezetecan
Login to view more data
100 Deals associated with Tizetatug rezetecan
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Platinum-Resistant Epithelial Ovarian Carcinoma | Phase 3 | CN | 10 May 2024 | |
| Platinum-Resistant Epithelial Ovarian Carcinoma | Phase 3 | CN | 10 May 2024 | |
| Ovarian Epithelial Carcinoma | Phase 3 | - | 15 Feb 2024 | |
| HR Positive/HER2 Negative/Node positive breast cancer | Phase 2 | CN | 01 Dec 2024 | |
| Human epidermal growth factor 2 negative carcinoma of breast | Phase 2 | CN | 01 Dec 2024 | |
| Metastatic breast cancer | Phase 2 | CN | 21 Oct 2024 | |
| Advanced Lung Non-Small Cell Carcinoma | Phase 2 | - | 01 Jun 2024 | |
| Salivary gland carcinoma | Phase 2 | CN | 26 Jul 2023 | |
| Advanced breast cancer | Phase 2 | CN | 30 Dec 2022 | |
| Advanced Malignant Solid Neoplasm | Phase 2 | CN | 30 Dec 2022 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
NCT05154604 (ESMO2024) Manual  | Phase 1 | 46 | SHR-A1921 3.0 mg/kg | qebkkvwxol(dopfsnjopc) = rdhcqoewit lhpjvirzmb (ozgrnotwjv, 86.8 - 100.0) View more | Positive | 15 Sep 2024 | |
SHR-A1921 2.0+2.0 mg/kg | qebkkvwxol(dopfsnjopc) = jhrqscqqyy lhpjvirzmb (ozgrnotwjv, 71.3 - 99.9) View more | ||||||
Phase 1 | 54 | SHR-A1921 3.0 mg/kg | udrmjbpmcw(pogcrhllcq) = mqbussnqww tfnkfabymp (pbmopgomjw ) View more | Positive | 14 Sep 2024 | ||
Phase 1 | Small Cell Lung Cancer TROP2 Expression | 17 | lsfggrfmbn(nvfldyzrxf) = qsykdsdrmw bwdisziani (zyuawzfoir, 15.2 - 58.3) View more | Positive | 08 Sep 2024 | ||
NCT05924256 (ASCO2024) Manual | Phase 2 | 21 | SHR-A1811(anti-HER2) 4.8 mg/kg | stbzngjnut(tfmikrbpwo) = fkslrsnpdb otarfynwyw (dmwwluxgjh ) View more | Positive | 24 May 2024 | |
rezvilutamide 240mg p.o. qd plus leuprolide 3.75mg s.c. | stbzngjnut(tfmikrbpwo) = jtzhbyifgv otarfynwyw (dmwwluxgjh ) View more | ||||||
NCT05154604 (AACR2023) Manual | Phase 1 | HR-positive/HER2-low Solid Tumors Second line | 38 | rzxtaicmlp(iybhrqfdff) = weijuvehxa hcsoybwojt (dknfwcmcpb ) View more | Positive | 14 Apr 2023 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free